"GMP manufacturing is the next step in our research and development of PT-401," stated DNAPrint Genomics President and Chief Executive Officer Richard Gabriel. "The GMP material produced by KBI BioPharma will be used to conduct preclinical studies required for a future Investigational New Drug Application, including toxicology studies and studies involving volunteers and patients." "The development of PT-401 is an exciting project for our Company, based on the success of our initial work on this compound," said Dr. Hector J. Gomez, M.D., Ph.D., Chief Medical Officer and Chairman of DNAPrint. DNAPrint Genomics obtained an exclusive, worldwide license from Harvard Medical School's Beth Israel Deaconess Medical Center in February 2005 for the development of a "Super" EPO, a more potent and longer acting form of Erythropoietin. The Company's goal is to utilize recent genomics and chemistry advances to develop next-generation test/drug combinations called "theranostics," designed to maximize efficacy and minimize side effects by tailoring and customizing medication for specific individuals and well-defined population sectors. About KBI BioPharma, Inc. KBI BioPharma, Inc., a leading contract process development and manufacturing service provider for the biopharmaceutical industry, accelerates and optimizes drug development and manufacturing programs. KBI BioPharma applies advanced biophysical and biochemical characterization techniques to develop scalable, robust processes resulting in products that exhibit optimal stability and biological activity. KBI BioPharma's scientific staff possesses the experience, including numerous IND and NDA submissions, to succeed in the challenges associated with all stages of drug development. KBI's services are performed in state-of-the-art laboratories housed in a 341,000 square foot facility in Durham, N.C. www.kbibiopharma.com. About DNAPrint Genomics, Inc. DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results. Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Contact: Company Contact: Richard Gabriel CEO and President 941 366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848   Source: DNAPrint Genomics, Inc.